|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 福林酚试剂法测定蛋白质显示文摘自1922年Wu(吴)提出用福林酚(Folin-酚)试剂测定蛋白质含量[1],已有许多采用这一试剂的改良分析操作进行血清陆”、抗原-抗体沉淀物[7-9]和胰岛素[10]中蛋白质含量测定的报道。虽然这一试剂以其灵敏度高和操作简便得到推荐,但并不适合普遍的生物化学应用。 | Lowry O H Rosebrough N J Farr A L Randall R J 陈祥娥 | 2011 | 食品与药品2011，13，3： | 34 |
| 2 | 应用药物代谢动力学模型评价前列腺不同组织的MRI增强作用显示文摘目的 :应用两室药物代谢动力学模型评价前列腺癌、前列腺增生和正常前列腺周围带的MRI增强特点。方法 :对 78例经病理组织学证实的前列腺癌 ,使用GESignaAdvantage 1.5T超导磁共振成像仪 ,采用FMPSPGR序列针对前列腺 (4层或 5层 )进行动态增强扫描 ,层厚 7mm ,层间间隔 2mm ,连续扫描采样 35次 ,Gd -DTPA经肘静脉置留导管按0 1mmol/kg体重在扫描开始的同时快速注射。将扫描数据传送的计算机工作站 ,应用两室药物代谢动力学模型进行分析 ,分别计算出不同ROI,前列腺癌、前列腺良性增生和正常前列腺周围带的最大增强指数 (maximenhancementindex)、对造影剂的吸收幅度 (amplitudeofuptake)、造影剂的交换率 (exchangerate)和造影剂分布指数 (distributionindex)。结果 :最大增强指数、对造影剂的吸收幅度、造影剂的交换率和造影剂分布指数以前列腺癌最高 ,前列腺增生次之 ,正常前列腺周围带最低。前列腺癌和正常前列腺周围带之间所有参数均存在极显著统计学差异 (P ≤ 0 .0 0 6 ) ,而前列腺增生和正常前列腺周围带之间所有参数也存在显著统计学差异 (P≤ 0 .0 3)。结论 :MRI药物代谢动力学模型能够更加准确的反映前列腺肿瘤组织和非肿瘤组织的血液供应特点 。 | 王滨 Martin Lowry Lindsay Wturnbull | 2001 | 医学影像学杂志2001，11，6： | 15 |
| 3 | 新生儿惊厥的诊断与处理(英文)显示文摘新生儿会发生各种形式的发作性运动,其中有些是癫癎性的惊厥,有些则不是。如何去识别是件困难的事。目前尚缺乏新生儿惊厥诊断与处理的全球性指南。该讲座在全面复习新生儿惊厥的文献并结合作者丰富的临床经验的基础上提出一个处理新生儿惊厥的方案。新生儿惊厥病因很多,缺氧-缺血性脑病和感染是最常见的原因,新生儿中风、遗传代谢病也逐渐被认识。病因是新生儿惊厥结局好坏的主要决定因素。视频-EEG是鉴别癫癎性惊厥与非癫癎惊厥的金标准。苯巴比妥依然是新生儿惊厥的首选药。足量苯巴比妥治疗无效时可考虑使用苯妥英、咪达唑仑或氯硝安定等。顽固性的惊厥,早期可试用吡哆醇、磷酸吡哆醛、叶酸和生物素治疗。对没有惊厥表现的脑电图发作的是否需要治疗有待于进一步的研究。 | Shashikant Subramani SESHIA Richard James HUNTSMAN Noel John LOWRY Mary SESHIA Jerome Yale YAGER Koravangattu SANKARAN 马丽亚 | 2011 | 中国当代儿科杂志2011，13，2： | 9 |
| 4 | 乙烯利对玉米的收获产量,子粒品质和倒伏的影响显示文摘乙烯利可以确定减少倒伏,维持或增加收获产量。1985与1986年研究了施用乙烯利比率和施用时间对玉米(Zea Mays L.)的收获产量、产量组成、倒伏与子粒品质的影响。乙烯利施于种在临近草地东北地中Pioneei杂种P_(3475)、P_(3377)和P_(3183)上。施乙烯利减少了玉米植株倒伏。P_(3377)与P_(3183)在TE时期(雄穗伸长时期)施乙烯利0.56公升/公顷者,倒伏由30%减少到9%,此比率结果使每穗少产生子粒52粒,粒重减轻7~17毫克。但是增加了收获果穗0.2~0.6个/平方米。除1986年在EE(雌穗伸长期)时施乙烯利没有影响外,增加乙烯利的施用比率,结果成线性地减少收获子粒产量。在此情况下,增施乙烯利比率,其结果是增加了每平方米收获果穗数补偿了每穗粒数与粒重的减少。1986年在TE时,两年在TE+6(雄穗伸长后6天)以及1985年在EE时施乙烯利结果是每公顷减少收获子粒产量接近1Mg(即1百万克或1千公斤)。施用乙烯利对玉米蛋白质含量,子粒的致密度和子粒易于产生破碎性有小的然面是显著的影响。施乙烯利有减少植株倒伏的作用,但它不能增加子粒产量,而且一般要减产。基于这些结果,在类似本研究的那些条件下,对栽培玉米生产者,施用一定的乙烯利,只有很小的刺激(或积极)意义。根据Zuben和Kang(1978)的估计,不管育种家怎样努力去培育抗倒伏品种,玉米茎秆倒伏年损失产量总数达5~25%。普遍认为:那些获得高产的条件:例如施高比率的氮素,高度密植,灌溉或多雨等,会促进倒伏,当发生倒伏收获子粒产量就减少(Zuben和Kang1978)。 | O. S. Norberg S. C. Mason S. R. lowry 贺绳武 | 1991 | 耕作与栽培1991，11，1： | 6 |
| 5 | ELISPOT辅助临床结核病诊断价值分析显示文摘目的探讨ELISPOT在结核病诊断中的应用价值。方法分离TB患者54例和非TB患者52例的外周血单个核淋巴细胞,并采用以结核分枝杆菌特异性蛋白ESAT-6和CFP-10为抗原的ELISPOT试验技术进行结核分枝杆菌(Mtb)特异性T淋巴细胞免疫反应的检测,同时做痰涂片、痰培养、PPD试验和胶体金法检测。以临床明确诊断为标准,比较分析评价不同检测方法的敏感度和特异度。结果 TB-ELISPOT的敏感度(Se)90.7%、特异度(Sp)96.15%、阳性预测值(PPV)0.96、阴性预测值(NPV)0.91、阳性似然比(+LR)23.55和阴性似然比(-LR)0.1;胶体金法的Se 59.26%、Sp 88.46%、PPV0.84、NPV 0.68、+LR 5.14和-LR 0.46;PPD试验的Se 64.81%、Sp 82.69%、PPV 0.80、NPV 3.74、+LR 0.69和-LR 0.43;痰涂片的Se 40.74%、Sp 100.00%、PPV 1.0、NPV 0.62、+LR>10和-LR0.52;痰培养的Se 25.93%、Sp 100.00%、PPV 1.0、NPV 0.57、+LR>10和-LR0.77。统计结果显示ELISPOT检测的敏感度明显高于其它常用结核病诊断方法。ELISPOT在痰涂片和痰培养阴性的TB患者中的阳性检出率分别为84.38%和87.5%。结论 ELISPOT是一种敏感度和特异度均较高的结核病免疫学辅助诊断方法,有助于提高诊断结核感染的阳性检出率,且耗时短,可作为临床结核病诊断尤其是菌阴结核病的重要辅助手段之一,具有较高的临床推广价值。 | 朱召芹 卢水华 王瑶娟 熊延青 刘晓茜 万延民 席秀红 许艳 张仁芳 施裕新 卢洪洲 Douglas Lowrie | 2011 | 中国人兽共患病学报2011，27，4： | 6 |
| 6 | 前列腺癌治疗前后动态增强MRI评价显示文摘目的 :应用MRI和动态增强MRI药物代谢动力学模型评价前列腺癌治疗前后的疗效 ,确定MRI的价值。方法 :对 16例经组织学证实的前列腺癌分别在治疗前后进行常规和动态增强MRI检查。治疗分别为单纯激素替代治疗 (7例 )和激素替代治疗加外放射治疗 (9例 )。MRI检查常规应用GESignaAdvantage 1.5T超导磁共振成像仪 ,静脉注射Gd DTPA(0 .1mmol/kg体重 )。应用两室药物代谢动力学模型分别计算肿瘤病灶、前列腺良性增生和正常前列腺周围带的最大增强指数、对比剂吸收幅度、对比剂的交换率和对比剂分布指数。结果 :治疗前后PSA由 39.5 4ng/ml降为 10 .39ng/ml(P =0 .0 4 6 ) ,由MRI测量获得的肿瘤体积明显缩小 (2 .85cm3 至 0 .84cm3 ,P =0 .0 1) ,前列腺良性增生和正常前列腺周围带也明显缩小 (P <0 .0 1)。治疗前后肿瘤病灶最大增强指数和对比剂分布指数降低 ,但未见统计学差异 ;对比剂吸收幅度和交换率明显降低 (P =0 .0 0 4 ,0 .0 0 2 )。前列腺良性增生的最大增强指数和对比剂分布指数降低 (P =0 .2 84 ,0 .2 2 1) ;对比剂吸收幅度和交换率明显降低 (P =0 .0 1,0 .0 0 7)。正常周围带的对比剂吸收幅度、交换率和分布指数明显降低 (P=0 .0 0 3,0 .0 1,0 .0 4 )。结论 :动态增强MRI能够全面反映前列腺癌治疗前? | 王滨 Martin LOWRY Lindsay W TURNBULL | 2003 | 医学影像学杂志2003，13，4： | 5 |
| 7 | Evaluating patients' perception of service quality at hospitals in nine Chinese cities by use of the ServQual scale显示文摘Objective: To investigate patients' perception of service quality at hospitals in nine Chinese cities and propose some measures for improvement. Methods: The ServQ ual scale method was used in a survey involving patients at out-patient and in-patient facilities in Shanghai, Chongqing, Chengdu, Nanning, Guilin and Laibin of Guangxi, Honghezhou of Yunnan, Wulumuqi of Xinjiang and Zhongshan of Guangdong. The data collected were entered and analyzed using SPSS 20.0. Statistical analyses included descriptive statistics, factor analyses, reliability analyses, product-moment correlations, independent-sample t-tests, One-way ANOVA and regression analyses. Results: The Kaiser-Meyer-Olkin value for the factor analysis of the scale was 0.979. The Cronbach's α for the reliability analysis was 0.978. All the Pearson correlation coei cients were positive and statistically signii cant. Visitors to out-patient facilities reported more positive perception tacilities on tangibles(t = 4.168, P(t = 1.979, P | Min Li Douglas Bruce Lowrie Cheng-Yu Huang Xiang-Chan Lu Ying-Chu Zhu Xing-Hua Wu Mayila Shayiti Qiong-Zhen Tan Hua-Ling Yang Si-Yuan Chen Pan Zhao Sheng-Hua He Xiu-Rong Wang Hong-Zhou Lu | 2015 | Asian Pacific Journal of Tropical Biomedicine2015，5，6： | 4 |
| 8 | 外周造血干细胞移植的新概念显示文摘大剂量化疗后自体骨髓移植(ABMT)已经用来治疗多种肿瘤,包括神经母细胞瘤、淋巴瘤、小细胞肺癌、睾丸癌、乳腺癌和急非淋白血病(ANLL),并可望取得成功。随着对外周循环中造血干细胞的认识,最近已认为外周干细胞移植(PSCT)可以替代ABMT。 | Lowry PA Tabbara IA 唐锁勤 | 1993 | 国外医学(输血及血液学分册)1993，16，4： | 3 |
| 9 | 新生儿的非癎样运动(摘译)显示文摘新生儿易出现各种非癎样运动如颤动、惊跳和良性新生儿睡眠性肌阵挛。而其他的异常运动如新生儿惊跳病就较为少见。然而这些运动的大多数预后良好,不会影响新生儿远期的神经发育。但临床医生对新生儿出现的一些惊跳现象仍需高度警惕,需与病理性惊跳鉴别,必要时行特殊的检查和治疗。 | Richard James HUNTSMAN Noel John LOWRY Koravangattu SANAKARAN 刘玲(译) | 2010 | 中国当代儿科杂志2010，12，9： | 2 |
| 10 | Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence显示文摘 | Todd H. Rockwood James M. Church James W. Fleshman Robert L. Kane Constantinos Mavrantonis Alan G. Thorson Steven D. Wexner Donna Bliss R.N. Ann C. Lowry | 1999 | Diseases of the Colon & Rectum1999，，12： | 2 |
| 11 | Protecting the delivery of heart failure: Regenerative Medicine/Stem Cell Therapeutics:Potential protections afforded by the Department of Health and Human Services and Health Resources Service Administration’s Bureau of Special Programs显示文摘Advances in stem cell science and potential clinical applications have brought clinical medicine closer to the actualization of Regenerative Medicine—an extension of transplantation of organs and cells and implantation of bioprosthetics and biodevices. The goal of such therapeutics will be intervention prior to onset of severe individual disability, enhance organ function and enhance patient performance status without incurring the economic impacts of standard organ transplantation. Regenerative Medicine is already demonstrating proof of principle or efficacy in restora- tion of myocardial contractility, joint mobility and function, immune competence, pulmonary function, immunologic self- tolerance, motor function and normal hemoglobin production with the next targets—diabetes mellitus (type I and type II), neurologic injury, hepatic dysfunction preparing to enter trials. Expenditures on health care needs of an aging U.S. citizenry approximate 20-25% ($3 trillion) of U.S. GDP currently and may to grow to 40% of U.S. GDP by 2025. As the potential of Regenerative Medicine is clinically realized, the societal impact and economic benefits will be disproportionately magnified in the economies of industrialized nations. The experi- ence of the Department of Health and Human Services (HHS), United Network for Organ Sharing (UNOS), the National Bone Marrow Donor Registry (NBMDR), and the National Vaccine Injury Compensation Programs (NVICP) can help ensure that as Regenerative Medicine strives to achieve clinical benefits while avoiding decimation of therapeutic options by product liability and medical malpractice concerns—concerns that crippled the U.S. vaccine manufacturing industry until the creation of the NVICP. The first 50 years of organ/cell/tissue transplantation demonstrates that clinical reality of allogeneic and autologous transplantation can antedate complete understanding of the basic science underlying successful transplantation. Product liability and medical malpractice liability have not impeded the development and growth of organ/cell/tissue transplanta- tion despite increased risks of infection, malignancy and cardiovascular disease in transplant recipients. Currently, human transplantation is only performed using FDA/CBER-approved, non-embryonic stem cells from peripheral blood, bone marrow or umbilical cord blood. Federal legislation passed in 2005 (HR2520 and S1317: The Bone Marrow and Cord Blood Cell Transplantation Program) authorizes the Secretary of Health and Human Services acting through the Director of HRSA to ensure uniform stem cell units distribution and outcomes monitoring via the federally-designated C.W. Bill Young Cell Transplant Program. Historically in the U.S., human biological therapies (vaccines, organ transplant and stem cell transplant) have re- quired federal protections to ensure continued distribution, fair access and avoidance of inhibitory product liability via protections afforded under the “stewardship” of the Secretary of Health and Human Services. The National Childhood Vaccine Injury Act of 1986 established the NVICP to equitably and expeditiously compensate individuals, or families of individuals, who have been declared injured by vaccines, thereby stabilizing a once imperiled vaccine supply by substan-tially reducing the threat of liability for vaccine companies, physicians, and other health care professionals who administer vaccines. Vaccines were the first biologics administered to U.S. citizens en masse and presage stem cell therapeutics (which may similarly be administered to millions) will similarly necessitate that a Stem Cell Injury Compensation Program (SCICP) will also need to be in place to demonstrate an intention to do good, an understanding that industry may do well, but that the health care consumer has a right of protection—all recognized from the outset. The Federal Tort Claims Act (FTCA) addresses liability claims via the Executive, Judicial and Legislative branches of Government, providing an um- brella of liability protection to other participants in the stem cell unit “chain of custody” under the FTCA—similar to the protection from product liability seen in organ and stem cell transplantation for the past 40-50 years. Efficacious development of regenerative medicine capabilities will mandate controlled access must first be provided for individuals with life-threatening diseases without therapeutic options or unable to benefit from or receive proven therapeutic options (ALS, cardiomyopathy and deemed not a candidate for heart transplantation, IDDM with hypoglyce- mic unawareness and no allogeneic source of traditional islet cell replacement available via HRSA) and mandates the prompt adoption of business and legal principles to ensure that the fate of the vaccine manufacturing industry does not become the fate of the stem cell therapeutics industry. If legal and regulatory concerns consume an increasing percentage of health care dollars that could be focused upon innovation, the Regenerative Medicine model will have not realized its full potential. The Diabetes Transplantation/Regenerative Medicine Model is the first organ to cell transplant model outside of oncology to demonstrate the regenerative medicine paradigm. Since all human tissues can be already recapitulated by human stem cells and key patent holders already exist, outlet or distribution of “more-than-minimally-manipulated stem cell units” as an IND approved under FDA/CBER guidelines can be accomplished via the current HHS/HRSA/Dept of Trans- plant methodology. As cardiovascular stem cell researchers develop human therapeutics utilizing more-than-minimally- manipulated stem cell products, they could be afforded protections from product liability historically enjoyed by the transplant community. Extending the Diabetes Transplant/Regenerative Medicine Model to the more than 5 million Americans with chronic heart failure, cell-based therapies to regenerate myocardial contractility could fill an existing void and be delivered in conjunction with and consistent with existing distribution of organs and tissues via HRSA/Department of Transplantation. | Gary S Friedman John S. Tomicki Neil Cohen Robert Marshal Philip Lowry Jeffrey Warsh | 2006 | Journal of Geriatric Cardiology2006，3，3： | 2 |
| 12 | Defining the nature of human pluripotent stem cell progeny显示文摘当人的 pluripotent 干细胞(hPSCs ) 能区分产生各种各样的房间类型的一件礼服,是清楚的时,在 vitro,开发怎么仔细反射那,是未知的哪个发生在 vivo。决定人的胚胎的干细胞(hESCs ) 和导致人的 pluripotent 干细胞(hiPSCs ) 是否做相等的子孙,并且是否也使房间成为那类似于导出织物的房间,我们执行了净化的 PSC 衍生物和他们的导出织物的对应物介绍的全面 transcriptome。表示介绍证明 hESCs 和 hiPSCs 在 hiPSC 子孙用外长的 reprogramming 因素为重新表示的神经、肝、间充质的系,和缺席做将近相同的子孙。不管多么与一个导出织物的对应物相比, hESCs 和 hiPSCs 的子孙维持了通常与早哺乳动物的开发联系的基因的一个子集的表示,不管产生的房间的类型。当 pluripotent 基因(OCT4, SOX2, REX1,和 NANOG ) 看起来在从 hPSCs 的区别之上立即是 silenced 时,对早胚胎(LIN28A, LIN28B, DPPA4,和其它) 通常独特的基因不是充分在 hPSC 衍生物的 silenced。从在早人的胎儿的织物(开发的 3-16 星期) 的表达式模式的这些数据和证据建议 hPSCs 的区分的子孙很早人的开发是反射的(< 6 个星期) 。这些调查结果为 hPSCs 能在早人的开发的 vitro 模型作为有用服务的想法提供支持,而且为疾病建模和 hPSC 衍生物的临床的申请提出重要问题。 | Michaela Patterson David N Chan IrisHa Dana Case Yongyan Cui Ben Van Hande Hanna KA Mikkola William E Lowry | 2012 | Cell Research2012，22，1： | 2 |
| 13 | Identification and Characterization of Murine Cytotoxie T Cells that Kill Mycobaeterium Tuberculosis显示文摘 | Silva C L Lowrie D B | 2000 | Infect Immune2000，68，6： | 1 |
| 14 | Methane hydrate:a frontier for exploration of new gas resources 显示文摘 | Max M D Lowrie A | 1996 | Journal of Petroleum Geology1996，19，2： | 1 |
| 15 | The No Conflict No Profit Rules and the Corporate Fiduciary: Challenging the Orthodoxy of Absolutism显示文摘 | EDMUNDS R LOWRY J | 2000 | Journal of Business Law2000，，3： | 1 |
| 16 | Protein measurement with the folin phenol reagent 显示文摘 | LOWRY O H ROSEBROUGH N J FARR A L | 1951 | Journal of Biological Chemistry1951，193，： | 1 |
| 17 | Protein measure-ment with the follin pheol reagent显示文摘 | Lowry O H Rosebrough N J Rarr A L | 1951 | J Biol Chem1951，193，： | 1 |
| 18 | C-reactive protein as an outcome predictor for maintenance hemodialysis patients显示文摘 | LOWRIE E G | 1998 | Kidney Int1998，54，： | 1 |
| 19 | The relative contribution of measured variables to death risk among hemodialysis patients,in Friedman E A:Death on hemodialysis:Preventable or inevitable显示文摘 | Lowrie EG | 1999 | Boston MA Kluwer academic Publisher1999，121，： | 1 |
| 20 | Neuromuscular blocking effects and train-of-four fade with cisatracurium: Comparison with other non-depolarizing relaxants显示文摘 | Carroll MT Mirakhur RK Lowry DW | 1998 | Anaesthesia1998，53，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员